Search

Displaying results 881 - 890 of 10000 in total
  1. Indication

    Decreased serum potassium levels

    go.drugbank.com/conditions/DBCOND0108215
    Drugs: Potassium lactate
    Synonyms: Decreased serum potassium levels
  2. Drug

    Povidone

    go.drugbank.com/drugs/DB11061
    ApprovedInvestigationalWithdrawn

    in eye drops. … It is also used in many technical applications with various roles as an adhesive, additive, and emulsifier.

    Mixtures: Rohto Sun and Sport, REFRESH % 1,4 + % 0,6 GÖZ DAMLASI, ÇÖZELTİ, 30 ADETCategories: Compounds used in a research, industrial, or household setting
  3. Drug

    Temozolomide

    go.drugbank.com/drugs/DB00853
    ApprovedInvestigational

    [L32033] Temozolomide was granted FDA approval on August 11, 1999, as an oral capsule and subsequently on February 27, 2009, as an intravenous injection. … [A229853, A229923] Temozomolide as an adjunct to radiotherapy followed by maintenance dosing remains the standard of care for both Glioblastoma and refractory anaplastic astrocytoma.

    Synonyms: 3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamideCategories: P-glycoprotein substrates with a Narrow Therapeutic Index
  4. Drug

    Perboric acid

    go.drugbank.com/drugs/DB13235
    Approved

    Perboric acid is mainly found in its salt form of sodium perborate and it can be found as a monohydrate or tetrahydrate. … [L1113] By the FDA, sodium perborate is approved as an ointment for the protection of poison ivy dermatitis.[L2764]

  5. Drug

    Albumin human

    go.drugbank.com/drugs/DB00062
    ApprovedInvestigational

    Human albumin is a small globular protein (molecular weight: 66.5 kDa), consisting of a single chain of 585 amino acids organized in three repeated homolog domains (sites I, II, and III). … This is a biosimilar drug to existing human serum albumin and was approved for a biological license at both 5% and 25% concentrations by the FDA on June 21, 2018 [L3101].

    Products: BUMINATE ALBUMINA AL 20 %, ALBUMINA HUMANA NORMAL AL 20%
  6. Drug

    Dulaglutide

    go.drugbank.com/drugs/DB09045
    ApprovedInvestigational

    therapy to diet and exercise in the management of 2 diabetes (T2DM). … Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct

    Products: TRULİCİTY 0.75 MG/0.5 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 2 ADET, TRULİCİTY 1.5 MG/0.5 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 2 ADET
  7. Drug

    Memantine

    go.drugbank.com/drugs/DB01043
    ApprovedInvestigational

    Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). … In December 2013, the G8 dementia summit concluded that dementia should be considered a global priority with the objective of developing a cure or a disease-modifying therapy by the year 2025 [L5953, F4366

    Mixtures: EMAXIN BASLANGIC SETI, 7+7+7+7 ADET, EMAXIN BASLANGIC SETI, 7+7+7+7 ADETProducts: Ran-memantine, MEMANTIN HCL AL 10MG FTA
  8. Drug

    Apomorphine palmitate

    go.drugbank.com/drugs/DB17202
    Experimental

    Synonyms: Hexadecanoic acid, 5,6,6a,7-tetrahydro-6-methyl-4h-dibenzo(de,g)quinoline-10,11-diyl ester, (r)-
  9. Drug

    Meloxicam

    go.drugbank.com/drugs/DB00814
    ApprovedInvestigationalVet approved

    It is a preferential COX-2 inhibitor, purportedly reducing the risk of adverse gastrointestinal tract effects, however, this is a topic of controversy.[A190198,A190201] … [A190189] With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is available in oral, transdermal, and intravenous formulations.

    Mixtures: OCAM PROTECT® 7.5 TABLETAS DE LIBERACIÓN RETARDADA, OCAM PROTECT ® 15 MG TABLETAS DE LIBERACION RETARDADAProducts: MELOXICAM AL 15MG TABL, MELOXICAM AL 7.5MG TABL
  10. Drug

    Omega-3-carboxylic acids

    go.drugbank.com/drugs/DB09568
    ApprovedWithdrawn

    The omega-3 carboxylic acid (OM3-CA) is a new formulation of omega-3 fatty acids that present an enhanced bioavailability in the treatment of dyslipidemia. … It is a complex mixture of the free fatty acids form containing eicosapentaenoic acid and docosahexaenoic acid as the most abundant species found in a proportion of 55% and 20% respectively.